Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency

Next Previous
Trial Profile

An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somavaratan (Primary)
  • Indications Growth disorders; Somatotropin deficiency
  • Focus Adverse reactions
  • Sponsors Versartis

Most Recent Events

  • 07 Mar 2018 Status changed from recruiting to discontinued as the primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved
  • 04 May 2017 Status changed from planning to recruiting.
  • 21 Feb 2017 According to Versartis media release, company anticipates to complete enrollment in 2H of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top